PBAC November Meeting - Community input to Hepatitis Australia Submission

Thank you for considering adding your voice to inform our submission to PBAC.  The medicines being considered at the November meeting of PBAC include:

  • Sofosbuvir (400mg) + velpatasvir (100mg) – Epclusa® by Gilead Sciences
  • Ledipasvir (90mg) + sofosbuvir (400mg) – Harvoni® by Gilead Sciences
  • Paritaprevir (75mg) + ritonavir (50mg) + ombitasvir (12.5mg) – Technivie® by AbbVie

The most significant thing to note regarding these applications is that it heralds the first pan-genotypic, interferon-free regimens for hepatitis C. Epclusa is a new treatment for genotypes 1-6 and Gilead is also seeking to expand the use of Harvoni to other genotypes. Technivie is for the treatment of genotype 4.

We have partnered with The Center for Community-Driven Research (CC-DR) to gather information from people living with hepatitis C who will benefit from the latest medicines to be considered by the Pharmaceutical Benefits Advisory Committee. In particular we would like input from people living with hepatitis C genotypes 2, 3, 4, 5 and 6.

By providing your details and consent below your contact details will be provided by Hepatitis Australia to the responsible person at CC-DR who will contact you to arrange a telephone interview.  The questions will relate to your experience of living with hep C, any previous treatment and what the new interferon-free treatments would mean for you.

If you wish to contribute please complete the form below, indicate if you give consent and then click submit.

Name *
Please indicate below if you give consent for Hepatitis Australia to provide your contact details to The Centre of Community-Driven Research so you can participate in an interview regarding the new hepatitis C medicines to be considered by PBAC.